All Outputs (2)

Making remote measurement technology work in multiple sclerosis, epilepsy and depression: survey of healthcare professionals (2022)
Journal Article
Andrews, J. A., Craven, M. P., Lang, A. R., Guo, B., Morriss, R., Hollis, C., & RADAR-CNS Consortium. (2022). Making remote measurement technology work in multiple sclerosis, epilepsy and depression: survey of healthcare professionals. BMC Medical Informatics and Decision Making, 22(1), Article 125. https://doi.org/10.1186/s12911-022-01856-z

BACKGROUND: Epilepsy, multiple sclerosis(MS) and depression are long term, central nervous system disorders which have a significant impact on everyday life. Evaluating symptoms of these conditions is problematic and typically involves repeated visit... Read More about Making remote measurement technology work in multiple sclerosis, epilepsy and depression: survey of healthcare professionals.

A randomised controlled trial investigating the clinical and cost-effectiveness of Alpha-Stim AID cranial electrotherapy stimulation (CES) in patients seeking treatment for moderate severity depression in primary care (Alpha-Stim-D Trial) (2022)
Journal Article
Patel, S., Boutry, C., Patel, P., Craven, M. P., Guo, B., Zafar, A., …Morriss, R. (2022). A randomised controlled trial investigating the clinical and cost-effectiveness of Alpha-Stim AID cranial electrotherapy stimulation (CES) in patients seeking treatment for moderate severity depression in primary care (Alpha-Stim-D Trial). Trials, 23(1), Article 250. https://doi.org/10.1186/s13063-022-06192-1

Background: Major depression is the second leading cause of years lost to disability worldwide and is a leading contributor to suicide. However, first-line antidepressants are only fully effective for 33%, and only 40% of those offered psychological... Read More about A randomised controlled trial investigating the clinical and cost-effectiveness of Alpha-Stim AID cranial electrotherapy stimulation (CES) in patients seeking treatment for moderate severity depression in primary care (Alpha-Stim-D Trial).